Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Meeting 10-Year DSCSA Serialization Mandate Requires Industry Big Push In Final Year

Executive Summary

HDA finds much progress to report in seventh annual Serialization Readiness Survey, but quite a lot of work remains for many drug manufacturers and distributors if they are to meet November 2023 compliance deadline.

You may also be interested in...



As Supply Chain Partners Ramp Up For November DSCSA Deadline, US FDA Gives Them Another Year

Potential distribution hitches could spark shortages of legitimate drugs if the system is not fully ready for package-level tracing requirements, US FDA says in delaying enforcement of the program a decade in the making. Poll shows supply chain partners were making significant progress in preparing for the 27 November deadline.

AAM Calls For Congress And FDA To End Shortages By Easing Up On Generics Quality, Pricing

Remote inspection alternatives could allow quicker resolution of quality issues that are holding up US imports, says association for generic drug manufacturers. AAM adds that adjusting a Medicaid inflation penalty could relieve unfair price pressures.

AAM Calls For Congress And FDA To End Shortages By Easing Up On Generics Quality, Pricing

Remote inspection alternatives could allow quicker resolution of quality issues that are holding up US imports, says association for generic drug manufacturers. AAM adds that adjusting a Medicaid inflation penalty could relieve unfair price pressures.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS147184

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel